A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.

BACKGROUND It is unclear whether treating brain metastasis before starting systemic chemotherapy can improve survival compared with upfront chemotherapy in non-small-cell lung cancer (NSCLC) with asymptomatic cerebral oligo-metastases. PATIENTS AND METHODS We undertook a randomized, controlled trial of 105 patients with one to four brain metastases, admitted to Samsung Medical Center between 2008 and 2013. Patients were randomly assigned to receive stereotactic radiosurgery (SRS) (49 patients) followed by chemotherapy or upfront chemotherapy (49 patients). The primary end point was overall survival (OS) and secondary end points included central nervous system (CNS) progression-free survival, progression to symptomatic brain metastasis and brain functional outcome. RESULTS The median age was 58 years (range, 29-85) with ECOG 0-1 performance status, and 40% of patients were never smokers. Most patients had adenocarcinoma, and about half of patients had only one brain metastasis, while the rest had multiple cerebral metastases. The median OS time was 14.6 months [95% confidence interval (CI), 9.2-20.0] in the SRS group and 15.3 months (95% CI, 7.2-23.4) for the upfront chemotherapy group (P = 0.418). There was no significant difference in time to CNS disease progression [median, 9.4 months (SRS) versus 6.6 months (upfront chemotherapy), P = 0.248]. Symptomatic progression of brain metastases was observed more frequently in the upfront chemotherapy group (26.5%) than the SRS group (18.4%) but without statistical significance. CONCLUSIONS Although this study included smaller sample size than initially anticipated due to early termination, SRS followed by chemotherapy did not improve OS in oligo-brain metastases NSCLC patients compared with upfront chemotherapy. Further study with large number of patients should be needed to confirm the use of upfront chemotherapy alone in this subgroup of patients. CLINICAL TRIALS NUMBER NCT01301560.

[1]  C. Loughrey,et al.  Stereotactic radiosurgery for the treatment of brain metastases: impact of cerebral disease burden on survival , 2012, British journal of neurosurgery.

[2]  Dirk Rades,et al.  Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline , 2012, Practical radiation oncology.

[3]  A. Sahgal,et al.  A meta‐analysis evaluating stereotactic radiosurgery, whole‐brain radiotherapy, or both for patients presenting with a limited number of brain metastases , 2012, Cancer.

[4]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Collette,et al.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jung-Il Lee,et al.  Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? , 2010, Lung cancer.

[7]  Y. Yatabe.  EGFR mutations and the terminal respiratory unit , 2010, Cancer and Metastasis Reviews.

[8]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Heung Tae Kim,et al.  Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first , 2008, Cancer.

[11]  Duk L. Na,et al.  Brief Screening for Mild Cognitive Impairment in Elderly Outpatient Clinic: Validation of the Korean Version of the Montreal Cognitive Assessment , 2008, Journal of geriatric psychiatry and neurology.

[12]  M. Rinaldi,et al.  Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases , 2007, Cancer.

[13]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[14]  S. Digumarthy,et al.  Does Initial Staging or Tumor Histology Better Identify Asymptomatic Brain Metastases in Patients with Non–small Cell Lung Cancer? , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  D. Kondziolka,et al.  Stereotactic radiosurgery for four or more intracranial metastases. , 2005, International journal of radiation oncology, biology, physics.

[16]  M. Cho,et al.  Screening of Brain Metastasis with Limited Magnetic Resonance Imaging (MRI): Clinical Implications of Using Limited Brain MRI During Initial Staging for Non-small Cell Lung Cancer Patients , 2005, Journal of Korean medical science.

[17]  A. Bricolo,et al.  Regional treatment of metastasis: role of radiosurgery in brain metastases--gamma knife radiosurgery. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Twijnstra,et al.  MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? , 2003, Lung cancer.

[19]  G. Scagliotti,et al.  Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[21]  J. Coast,et al.  Inter-rater reliability of the Barthel ADL Index: how does a researcher compare to a nurse? , 2000, Clinical rehabilitation.

[22]  D. Kondziolka,et al.  MR imaging response of brain metastases after gamma knife stereotactic radiosurgery. , 1999, Radiology.

[23]  Duk L. Na,et al.  A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients , 1997 .

[24]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[25]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[26]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[27]  Mahoney Fi,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 1965 .

[28]  Julio Sánchez de Cos,et al.  Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. , 2009, Lung cancer.

[29]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.